Press Releases

February 4, 2026

TAE Life Sciences and Bozlu Holding Announce Exclusive Distribution Agreement to Expand TAE Life Sciences’ Next-Gen Targeted Cancer Treatment Platform Across Turkiye, Eastern Europe, and Central Asia

February 5, 2026 – Irvine, Calif. and Istanbul, Turkiye – TAE Life Sciences US, LLC (“TAE Life Sciences”), a leader in accelerator-based boron neutron capture therapy (“BNCT”) for precision oncology, today announced the signing of an exclusive distribution agreement with Bozlu Holding A.S. (“Bozlu”), a diversified holding company headquartered in Istanbul, Turkiye, with more than 35 years of expertise in healthcare services. TAE Life Sciences is a minority-owned subsidiary of TAE Technologies, Inc (“TAE Technologies”). TAE Technologies is a leading fusion power company based in Southern California, USA.

BNCT is an advanced form of targeted radiation therapy that selectively destroys cancer cells while minimizing damage to surrounding healthy tissue. TAE Life Sciences’ accelerator-based BNCT platform and proprietary boron-10 drugs are designed to support hospital-based deployment.

Under the terms of the exclusive distribution agreement, Bozlu is appointed as the exclusive distributor of TAE Life Sciences’ Alphabeam™ BNCT platform and associated boron target drug candidates across a broad territory including Turkiye, Eastern Europe, and Central Asia, and will be responsible for marketing, promoting, distributing, and selling the BNCT system, as well as supporting the deployment of the technology at an initial clinical site to enable clinical trial research and regulatory approval in the region.

“This agreement represents a significant milestone in our global expansion strategy and underscores the growing international demand for BNCT as a highly targeted cancer treatment,” said Rob Hill, Chief Executive Officer of TAE Life Sciences. “Bozlu brings deep regional expertise, strong healthcare relationships, and the operational capabilities required to support both clinical research and commercialization. Together, we aim to accelerate patient access to BNCT in regions where advanced oncology solutions are urgently needed.”

Bozlu will work closely with TAE Life Sciences to engage leading hospitals, academic institutions, and regulatory authorities to establish clinical programs and support long-term adoption of BNCT technology.

“We are proud to partner with TAE Life Sciences to introduce this groundbreaking cancer treatment platform to Turkiye and neighboring markets,” said Ismail Dernek, Board Member of Bozlu. “BNCT represents a transformative opportunity for oncology care, and we believe this collaboration positions our region at the forefront of next-generation precision medicine.”

About TAE Life Sciences

TAE Life Sciences is pioneering next-generation BNCT with a pipeline of proprietary boron drugs and accelerator-based neutron systems, advancing precision radiation therapy and combination regimens to improve survival for patients with hard-to-treat cancers. TAE Life Sciences is a minority-owned subsidiary of TAE Technologies. TAE Technologies is a leading fusion power company based in Southern California, USA. For more information, visit www.taelifesciences.com.

About Bozlu

Bozlu is a Turkish conglomerate with diversified operations across healthcare, advanced technology services and industrial sectors. The Group is particularly active in oncological diagnosis and treatment, delivering high-technology solutions through its affiliated companies and contributing to broader healthcare innovation. Bozlu has a strong track record of executing complex, high-tech projects and supporting sustainable, regional growth initiatives. For more information, visit www.bozlu.com.

April 23, 2025

TAE Life Sciences Secures Distribution Agreement with Transmedic Group to Bring Boron Neutron Capture Therapy to Southeast Asia

April 23, 2025 – Foothill Ranch, CA – TAE Life Sciences (TLS), a pioneer in next-generation cancer treatment technologies, is pleased to announce a strategic partnership with Transmedic, a leading medical technology distributor in Southeast Asia, to bring Boron Neutron Capture Therapy (BNCT) to the region. This collaboration marks a significant milestone in expanding access to TLS’s cutting-edge Alphabeam™ BNCT system, a novel particle therapy platform designed for treating invasive, recurrent, and difficult-to-treat cancers.

Transmedic will represent TAE Life Sciences in key Southeast Asian markets, providing clinical, operational, and regulatory support to bring Alphabeam BNCT to regional hospitals and cancer centers. The partnership will focus initially on countries such as Singapore, Malaysia, Hong Kong, and Thailand, where demand for advanced oncology treatment options continues to grow.

“We’re thrilled to partner with Transmedic, whose established presence and deep expertise in the region make them an ideal collaborator for expanding BNCT in Southeast Asia,” said Rob Hill, CEO of TAE Life Sciences. “Our Alphabeam system is uniquely designed for hospital-based environments and offers new hope for patients with aggressive tumors that are resistant to traditional treatments.”

BNCT is a biologically targeted form of radiation therapy that selectively destroys tumor cells while minimizing damage to healthy tissue. The Alphabeam system is the first and only accelerator-based BNCT platform developed specifically for clinical use and optimized for integration within modern healthcare settings.

“Transmedic is excited to work with TAE Life Sciences to introduce BNCT to our region,” said Kristine James, CEO of Transmedic. “This partnership aligns with our mission to bring innovative medical solutions to Southeast Asia and help improve outcomes for patients facing the most challenging cancers.”

This agreement is part of TAE Life Sciences’ broader global expansion strategy, building on recent collaborations in Asia, Europe, and North America to make BNCT more accessible worldwide.

About TAE Life Sciences
TAE Life Sciences is a biotechnology company pioneering the development of accelerator-based BNCT solutions for treating aggressive and treatment-resistant cancers. The company’s Alphabeam BNCT system and novel boron drugs are designed to enable safe and effective BNCT treatment worldwide. More information about TAE Life Sciences is available at taelifesciences.com

About Transmedic
Transmedic connects the world’s leading healthcare solutions to the needs of people across Asia. Headquartered in Singapore, we are a leading independent distributor of innovative medical technologies, specializing in therapeutic areas such as Radiation Oncology, Cardiovascular, Orthopaedics, In-vitro Diagnostics, Ophthalmology, Blood Therapy, Endovascular, and Abdo-Pelvic. With over 40 years of local expertise, we provide healthcare professionals and institutions throughout ASEAN and Hong Kong with globally sourced solutions, trusted networks, and dedicated support to enhance patient care. Transmedic’s regional presence spans Singapore, Malaysia, Thailand, Indonesia, Hong Kong, the Philippines, and Vietnam, empowering healthcare systems for better outcomes. Learn more: transmedicgroup.com

April 1, 2025

TAE Life Sciences Partners with alphaXRT to bring Boron Neutron Capture Therapy to Australia and New Zealand

April 1, 2025 — Irvine, CA – TAE Life Sciences (TLS), a leader in next-generation Boron Neutron Capture Therapy (BNCT) solutions, has announced a distribution agreement with alphaXRT, a premier provider of advanced radiation therapy technologies. Under this partnership, alphaXRT will distribute TAE Life Sciences’ Alphabeam™ BNCT system and novel boron drugs, while also providing associated services across Australia and New Zealand.

As part of the agreement, alphaXRT will hold the regulatory certificate for BNCT in the region, ensuring compliance with local medical and regulatory standards. This collaboration will expand access to BNCT, offering patients with difficult-to-treat cancers an innovative and targeted radiation therapy option.

“This agreement with alphaXRT marks a significant step forward in making BNCT more accessible to patients in Australia and New Zealand,” said Rob Hill, CEO of TAE Life Sciences. “With alphaXRT’s deep expertise in radiation oncology and regulatory affairs, we are confident that this partnership will drive adoption and establish BNCT as a key treatment modality in the region.”

The Alphabeam BNCT system is a cutting-edge accelerator-based neutron source designed to deliver safe, effective, and precisely targeted radiation therapy. By leveraging boron-10 drugs, BNCT enables selective tumor destruction while preserving surrounding healthy tissue—making it a promising option for patients with recurrent or treatment-resistant cancers.

“TAE Life Sciences is at the forefront of BNCT innovation, and we are thrilled to be their distributor in Australia and New Zealand,” said Richard Neale, Managing Director of alphaXRT. “We look forward to working closely with hospitals and cancer treatment centers to bring this transformative therapy to more patients.”

This partnership further underscores TAE Life Sciences’ commitment to expanding global access to BNCT and advancing the future of radiation oncology.

About alphaXRT
alphaXRT was founded in 1990 by Richard Neale, who identified an opportunity to introduce cutting-edge radiation oncology technologies into Australasia, giving clinicians access to the world’s most innovative, precise, personalized treatments to give every patient a future with options. Today alphaXRT is the leading independent supplier of equipment to all radiation oncology departments in Australia and New Zealand. Learn more at alphaxrt.com.

January 9, 2025

TAE Life Sciences and Kyoto University Achieve Breakthrough Preclinical Results in Boron Neutron Capture Therapy (BNCT) with Promising Implications for Cancer Treatment

November 13, 2024 — Irvine, CA – TAE Life Sciences (TLS), in collaboration with Kyoto University and Principal Investigator Dr. Fuyuhiko Tamanoi, is thrilled to announce groundbreaking preclinical results in Boron Neutron Capture Therapy (BNCT). Utilizing TAE Life Science’s novel boron-10 drugs and Kyoto University Research Reactor (KURR) neutron source has generated significant pre-clinical data that may redefine the potential of BNCT in cancer treatment.

Recently published in the Journal of Medicinal Chemistry (J. Med. Chem. 2023, 66, 13809−13820) and complemented by a newly submitted manuscript to ACS Central Science, our
research highlights a remarkable phenomenon known as the abscopal effect. This effect, where localized radiation treatment results in the shrinkage of tumors at untreated sites, holds profound implications for treating metastatic and micro-metastatic cancer.

In a key study using immune-competent balb/c mice, BNCT treatment of subcutaneous tumors on one leg completely inhibited tumor growth when the same tumor cells were reintroduced to the opposite leg two weeks post-treatment. These results, some of the most impressive preclinical data seen to date, suggest that BNCT can stimulate an immune response capable of generating memory cells to prevent tumor recurrence at distant sites.

"In one experiment, a mouse colon tumor was grown in the leg of a mouse and a second tumor was grown in its shoulder. BNCT was applied to the tumor in the leg, while the shoulder tumor was shielded from treatment. Remarkably, the untreated shoulder tumor exhibited a 34% reduction and slower growth rate compared to the control group, highlighting a potential systemic effect of BNCT."

“While the abscopal effect is not new in radiation oncology, these results with BNCT represent a significant step forward”, said Dr. Sunil Krishnan, Radiation Oncologist and Professor at the Center for Translational Cancer Research at UT Health Houston. “What’s particularly exciting is that this level of immune response and tumor control has not traditionally been observed with standard x-ray-based radiation therapy. It underscores the potential for BNCT to not only address
primary tumors but also impact metastatic disease in a way we haven’t seen before.”

Further investigations are underway to explore the mechanisms behind these results, focusing on the role of dendritic cells, T-cells, and macrophages in immune memory. Additionally, TAE Life Sciences is evaluating the combination of BNCT with immune checkpoint inhibitors, such as anti-CTLA4, anti-PD1, and anti-PDL1, to enhance outcomes in tumors with both “hot” (active immune profile) and “cold” (inactive immune profile) immune phenotypes.

"We are excited to demonstrate both the vaccine effect and the abscopal effect in preclinical BNCT experiments," said Kendall Morrison, Chief Scientific Officer at TAE Life Sciences.
"This research reinforces BNCT's potential not only as a localized therapy but also as a treatment capable of addressing metastatic cancer. Combining BNCT with immunotherapy agents could significantly transform cancer treatment outcomes."

If these preclinical results can be translated to clinical applications, it could pave the way for improved responses to immune checkpoint blockade therapies, particularly for challenging “cold” tumors.

About TAE Life Sciences
TAE Life Sciences is dedicated to pioneering advancements in Boron Neutron Capture Therapy (BNCT), a unique cancer treatment modality. Through innovative compounds, cutting-edge
neutron sources, and collaborations with leading institutions, TAE Life Sciences aims to offer patients a targeted, effective, and minimally invasive cancer treatment option. More information about TAE Life Sciences is available at taelifesciences.com.

November 13, 2024

TAE Life Sciences and Stella Pharma Announce Strategic Agreement for Development and Commercialization of BPA for BNCT Cancer Therapy in the USA and Europe

November 13, 2024 — Irvine, CA – TAE Life Sciences (TLS), a leader in developing boron neutron capture therapy (BNCT) technology and associated innovative boron target drugs, and Stella Pharma, the pioneering developer of boronophenylalanine (BPA) under the product name, Steboronine®, for BNCT, are pleased to announce a strategic collaboration focused on the development, commercialization and expansion of BNCT using BPA in the United States and European markets.

Stella Pharma’s BPA drug is the world’s first and only clinically approved boron drug for BNCT, marking a breakthrough in cancer treatment. Japan became the first country to approve BNCT for the treatment of head and neck cancers, using Stella Pharma’s pioneering BPA drug. Now, Stella Pharma, as the leading producer and supplier of BPA, has joined forces with TAE Life Sciences to expand the adoption of BNCT worldwide.

Supporting the Future of BNCT Therapy

The collaboration objectives include extensive international cooperation in the development and commercialization of BNCT and BPA across the USA and Europe with clinical trials anticipated to begin in 2026. TLS will serve as the exclusive commercial partner for Stella Pharma’s BPA in these regions, representing a significant expansion of BNCT accessibility outside of Asia.

“Our partnership with Stella Pharma combines our shared commitment to advancing BNCT as a viable cancer treatment for patients worldwide,” said Rob Hill, CEO of TAE Life Sciences. “We are excited to bring the proven benefits of BPA to U.S. and European healthcare institutions and to support BNCT globally with this powerful therapeutic solution.”

Both companies have also committed to supporting BNCT equipment vendors across all markets in implementing BPA-based BNCT treatments. By fostering partnerships within the BNCT ecosystem, TLS and Stella Pharma aim to enhance the clinical reach of BNCT in treating recurrent head and neck cancers and advancing clinical studies for other cancers, including brain, skin, breast, esophagus, and lung cancers.

“Our alliance with TAE Life Sciences marks a significant step in expanding the reach of BPA-based BNCT treatments beyond Asia,” said Koki Uehara, President and Chief Operating Officer of Stella Pharma. “We look forward to collaborating internationally to develop and commercialize BNCT and aim to deliver this advancing cancer treatments to patients and their families worldwide.”

Exploring Future Opportunities Together

Stella Pharma and TAE Life Sciences share a vision of advancing BNCT treatment for hard-to-treat cancers and pledge to explore additional areas for collaboration. Through this alliance, they seek to accelerate innovation, expand treatment options, and ultimately improve outcomes for cancer patients worldwide.

For more information about TAE Life Sciences, Alphabeam, and the company’s proprietary boronated BNCT drugs, please visit taelifesciences.com.

About TAE Life Sciences
TAE Life Sciences is a privately held biotechnology company committed to developing a new biologically targeted radiation therapy based on Boron Neutron Capture Therapy (BNCT). TAE Life Sciences is the only company developing the next-generation targeted boron drugs and low-energy accelerator-based neutron system optimized for an in-hospital BNCT program that delivers cancer-killing radiation with cellular-level precision to treat patients with aggressive and refractory cancers. TAE Life Sciences’ Alphabeam™ BNCT system and proprietary boronated drugs are still in the investigational stage, and not available commercially. More information about TAE Life Sciences is available at taelifesciences.com.

June 4, 2024

TAE Life Sciences Appoints Commercial Leadership Team and Announces Distribution Deal with Radiosurgery Global

Committed to Driving the Adoption of Boron Neutron Capture Therapy for Cancer, TAE Life Sciences Bolsters Resources to Expand the Number of Alphabeam Clinical Installations Worldwide

IRVINE, Calif., June 4, 2024 – TAE Life Sciences, a pioneer in advancing Boron Neutron Capture Therapy (BNCT) for cancer treatment, proudly announces the formation of its new commercial leadership team, dedicated to driving the company’s expansion across the Americas, APAC (Asia-Pacific) and EMEAI (Europe, Middle East, Africa, and India). With extensive experience and expertise with their respective markets, each member of this team will serve as the general manager for their region. With a focused goal of expanding the company’s global footprint, the commercial leadership team is poised to enhance market reach, foster strategic partnerships, and ultimately expand the number of Alphabeam BNCT installations at clinical sites worldwide.

TAE Life Sciences’ commercial leadership team members:

Anna Theriault, GM for the Americas, and Global VP of Marketing: A tenured radiation oncology business and marketing executive, Anna brings a wealth of experience in driving adoption in evolving radiation therapy, data, and oncology solutions from previous senior leadership roles at Accuray and Elekta.
Michael Sandhu, GM for Europe, the Middle East, Africa, and India: With over 30 years of experience in radiation therapy, Michael founded remediumRT AG and held key roles at Varian Medical Systems. He specializes in emerging market growth and government negotiations.
Peter Stafford, GM for Asia Pacific: With over 15 years of experience in radiation oncology and biopharmaceuticals, Peter has held key technical and business roles at Accuray and Pharmaceutical Product Development, Inc.

In a strategic move to bolster its presence in India, TAE Life Sciences is excited to announce Radiosurgery Global (RSG) as its new distribution partner for the country. RSG excels in providing comprehensive support through a network of skilled consultants, partners, and advisors specializing in sales channels, project management, construction, digital and print marketing, investment advisory, engineering, service, and financing.

“TAE Life Sciences’ innovative Alphabeam BNCT system has the potential to revolutionize cancer care with its unparalleled treatment accuracy. We are excited to combine their cutting-edge solutions with our established radiation oncology distribution infrastructure and sales network to advance the field of radiation oncology in India,” said Kapil Kalra, Managing Director, Radiosurgery Global.

Working with RSG will help TAE Life Sciences to strategically target both seasoned professionals in radiation oncology as well as the institutions adopting the latest cancer care innovations in India. With RSG’s proven expertise and extensive experience, this partnership is set to significantly enhance TAE Life
Sciences’ reach and growth in a key market.

“At TAE Life Sciences, our mission is to make transformative advancements in cancer treatment accessible worldwide. The appointment of our new commercial leadership team and expansion of our distribution partners are pivotal steps toward realizing this vision,” said Rob Hill, CEO, TAE Life Sciences.

For more information about TAE Life Sciences, Alphabeam, and the company’s proprietary boronated BNCT drugs, please visit taelifesciences.com.

April 3, 2024

TAE Life Sciences’ Neutron Beam System Receives Acceptance Enabling the Start of BNCT Clinical Trials in China

A Key Component of Neuboron’s NeuPex AB-BNCT System, TAE Life Sciences’ Neutron Beam System Receives Performance Acceptance and Passes Class III Registration Inspection

IRVINE, Calif., April 3, 2024 – TAE Life Sciences, a pioneer in advancing Boron Neutron Capture Therapy (BNCT) for cancer treatment, proudly announces the successful completion of acceptance testing and regulatory registration inspection of its accelerator- based neutron beam system (NBS), marking a significant milestone in BNCT global market adoption. Developed and manufactured in the United States, TAE Life Sciences’ NBS has met all specifications outlined by Neuboron Medical and the local regulatory body, enabling human BNCT clinical trials to begin this month in China.

The completion of acceptance testing underscores TAE Life Sciences’ commitment to international safety and efficacy standards, making it the first US company to have its system achieve such recognition. This major technological progress demonstrates how TAE Life Sciences has solidified its leading position in the growing field of BNCT. As the company progresses in establishing Alphabeam BNCT sites worldwide, collaborating with Neuboron to provide them with a Neutron Beam System has paved a distinctive pathway into the Chinese market.

“We worked closely with Neuboron to ensure our accelerator-based NBS precisely delivered the results required for BNCT and are thrilled to have successfully completed acceptance testing and regulatory inspection,” stated Rob Hill, CEO at TAE Life Sciences. “This milestone not only demonstrates our dedication to delivering cutting-edge cancer treatment solutions, but also signifies our ability to meet rigorous international standards.”

Additionally, the Beijing Institute of Medical Device Testing has completed registration testing of the full Neuboron Medical’s NeuPex AB-BNCT system, which includes TAE Life Science’s NBS. This milestone marks a significant regulatory approval step, enabling Neuboron to move forward with clinical trials in China. Neuboron will commence clinical trials at Xiamen Humanity Hospital.

The latest market analysis report by Intel Market Research forecasts robust growth in the BNCT market, with global revenues projected to reach $2.2 billion by 2030. TAE Life Sciences, alongside industry leaders such as Neuboron, Sumitomo, and others, is poised to play a pivotal role in driving this exponential growth.

As the BNCT market continues to expand, TAE Life Sciences remains at the forefront of innovation, delivering transformative solutions to cancer patients worldwide.

For more information about TAE Life Sciences, Alphabeam, and the company’s proprietary boronated BNCT drugs, please visit taelifesciences.com.

For more information about Neuboron and its technologies, please visit neuboron.com/.

About TAE Life Sciences
TAE Life Sciences is a privately held biotechnology company committed to developing a new biologically targeted radiation therapy based on Boron Neutron Capture Therapy (BNCT). TAE Life Sciences is the only company developing the next-generation targeted boron drugs and low-energy accelerator-based neutron system optimized for an in-hospital BNCT program that delivers cancer-killing radiation with cellular-level precision to treat patients with aggressive and refractory cancers. TAE Life Sciences’ Alphabeam neutron system and targeted boron drugs are currently in development and have not been approved for sale. More information about TAE Life Sciences is available at taelifesciences.com.

March 13, 2024

TAE Life Sciences Awarded Patent for Borylated Amino Acid Compositions for Boron Neutron Capture Therapy

The Granted Patent Covers the Compositions of BTS And BTS(OMe) And Novel Methods Of
Their Production

Irvine, Calif., November 7, 2024 – TAE Life Sciences, a leading innovator in cancer treatment technologies, today announced that the United States Patent and Trademark Office (USPTO) has granted the company’s U.S. Patent No. US 11,884,688 B2, for its groundbreaking borylated amino acid compositions comprising tyrosine derivatives BTS and BTS(OMe) for use in Boron Neutron Capture Therapy (BNCT). This new patent underscores TAE Life Sciences' commitment to advancing biologically targeted radiation therapy and marks a significant
milestone in the field of radiation therapy.

Boron Neutron Capture Therapy (BNCT) is a promising approach for the treatment of cancer and other diseases, utilizing boron-containing compounds to selectively deliver radiation to tumor cells while sparing healthy tissue. TAE Life Sciences' patented borylated amino acid compounds, BTS and BTS(OMe), may offer an effective means of enhancing efficacy of BNCT, potentially opening new avenues for targeted treatments for cancer and immunological disorders.

“This patent represents a significant milestone for TAE Life Sciences, validating the innovative work of our research and development teams. We are excited about the potential impact of BTS and BTS(OMe) in advancing BNCT cancer treatment and improving patient outcomes.” Rob Hill, CEO at TAE Life Sciences.

The patent covers not only the compositions of BTS and BTS(OMe) but also novel methods of their production, enabling scalable manufacturing processes to meet the growing demand for BNCT agents. With this patent, TAE Life Sciences solidifies its position as a leader in radiation therapy innovation, poised to transform the landscape of cancer treatment.

For more information about TAE Life Sciences, Alphabeam, and the company’s proprietary boronated BNCT drugs, please visit taelifesciences.com.

About TAE Life Sciences
TAE Life Sciences is a privately held biotechnology company committed to developing a new biologically targeted radiation therapy based on Boron Neutron Capture Therapy (BNCT). TAE Life Sciences is the only company developing the next-generation targeted boron drugs and low-energy accelerator-based neutron system optimized for an in-hospital BNCT program that delivers cancer-killing radiation with cellular-level precision to treat patients with aggressive and refractory cancers. TAE Life Sciences’ Alphabeam neutron system and targeted boron drugs are currently in development and have not been approved for sale. More information about TAE Life Sciences is available at taelifesciences.com.

November 8, 2023

TAE Life Sciences Earns Oncology Innovation of the Year Award

Earning the BioTech Breakthrough Award for Oncology Innovation of the Year validates the progress TAE Life Sciences has made in readying its Alphabeam BNCT system for clinical trials worldwide

Irvine, Calif., November 8, 2023 – TAE Life Sciences, a pioneer in advancing Boron Neutron Capture Therapy (BNCT) for cancer treatment, proudly announces it has earned the 2023 Biotech Breakthrough Award for Oncology Innovation of the Year. This prestigious accolade acknowledges TAE Life Sciences' pioneering work in radiation oncology and highlights the role its innovative Alphabeam™ Neutron System and proprietary boronated drugs are playing in making Boron Neutron Capture Therapy (BNCT) a mainstay of modern oncology.

“The advancements we’ve made hold the potential to be applied across a broader range of clinical scenarios, expanding the horizons of BNCT as a next-generation cancer treatment,” said TAE Life Sciences' CEO, Rob Hill. “Thank you to BioTech Breakthrough for validating our work. With our BNCT approach, empowered by Alphabeam and boronated drugs, we are leading the way to faster, more effective, and safer treatment options for a range of difficult-to-treat cancers that is sure to enhance patient outcomes and save lives.”

The Biotech Breakthrough Award symbolizes our commitment to shaping the future of cancer treatment. TAE Life Sciences' Alphabeam Neutron System generates high-intensity, precision-focused, low-energy neutrons, revolutionizing BNCT. This innovative approach provides highly targeted cancer treatment with minimal collateral damage, reducing the impact on healthy tissue.

At the core of this achievement is Alphabeam's capacity to deliver thermal neutrons, enabling the interaction between boron-10 and tumor cells. This interaction results in the release of high-energy alpha particles and lithium nuclei, destroying tumor cell DNA and ultimately killing the cancer cells while sparing surrounding healthy tissue. This groundbreaking technology not only holds promise for head and neck cancers but also eliminates the need for dangerous nuclear reactors, making it a safer, cost effective, and versatile alternative for cancer treatment.

“TAE Life Sciences is spearheading pivotal advancement in biotech. By combining the precision of Alphabeam with the selectivity of their boronated drugs, the company is setting the stage for a paradigm shift in cancer therapy,” said Bryan Vaughn, Managing Director of BioTech Breakthrough Awards. “Historically, BNCT required a nuclear reactor as a neutron source, which is extremely expensive and impractical for hospitals to adopt and maintain. TAE’s Alphabeam system eliminates this need and offers flexibility for various clinical settings. This versatility, coupled with its potential to treat various types of cancers, grants TAE our ‘Oncology Innovation of the Year’ award.”

Complementing Alphabeam is TAE Life Sciences' proprietary boronated drug, TC220, which offers numerous advantages over conventional boronophenylalanine (BPA). Pre-clinical studies have shown TC220's superior ability to deliver boron effectively to tumor cells, expanding the horizons of BNCT as a next-generation cancer treatment.

The Alphabeam system's versatility enhances its market potential, as it can be integrated into existing medical infrastructures and offers the promise of reducing cancer treatment costs. This groundbreaking technology is being deployed to cancer hospitals worldwide, signaling a transformative shift in oncology.

TAE Life Sciences is committed to advancing the frontiers of oncology through innovation and patientfocused care. This award is a testament to the company's dedication to making a profound and positive impact in biotechnology.

For more information about TAE Life Sciences, Alphabeam, and the company’s proprietary boronated BNCT drugs, please visit taelifesciences.com.

About TAE Life Sciences
TAE Life Sciences is a privately held biotechnology company committed to developing a new biologically targeted radiation therapy based on Boron Neutron Capture Therapy (BNCT). TAE Life Sciences is the only company developing the next-generation targeted boron drugs and low-energy accelerator-based neutron system optimized for an in-hospital BNCT program that delivers cancer-killing radiation with cellular-level precision to treat patients with aggressive and refractory cancers. TAE Life Sciences’ Alphabeam neutron system and targeted boron drugs are currently in development and have not been approved for sale. More information about TAE Life Sciences is available at taelifesciences.com.

Have questions about BNCT? Get answers on our new BNCT Forum